- Home
- DUO vs CLDI Comparison
DUO vs CLDI Comparison
Compare DUO & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUO
- CLDI
- Stock Information
- Founded
- DUO 2011
- CLDI 2014
- Country
- DUO China
- CLDI United States
- Employees
- DUO N/A
- CLDI N/A
- Industry
- DUO Real Estate
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DUO Finance
- CLDI Health Care
- Exchange
- DUO Nasdaq
- CLDI Nasdaq
- Market Cap
- DUO 17.1M
- CLDI 14.0M
- IPO Year
- DUO 2019
- CLDI N/A
- Fundamental
- Price
- DUO $0.27
- CLDI $0.48
- Analyst Decision
- DUO
- CLDI Strong Buy
- Analyst Count
- DUO 0
- CLDI 2
- Target Price
- DUO N/A
- CLDI $15.00
- AVG Volume (30 Days)
- DUO 3.1M
- CLDI 386.9K
- Earning Date
- DUO 05-02-2025
- CLDI 05-13-2025
- Dividend Yield
- DUO N/A
- CLDI N/A
- EPS Growth
- DUO N/A
- CLDI N/A
- EPS
- DUO 0.47
- CLDI N/A
- Revenue
- DUO $46,458,330.00
- CLDI N/A
- Revenue This Year
- DUO N/A
- CLDI N/A
- Revenue Next Year
- DUO N/A
- CLDI N/A
- P/E Ratio
- DUO $0.48
- CLDI N/A
- Revenue Growth
- DUO 6.61
- CLDI N/A
- 52 Week Low
- DUO $0.20
- CLDI $0.35
- 52 Week High
- DUO $4.67
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- DUO 34.53
- CLDI 39.82
- Support Level
- DUO $0.21
- CLDI $0.41
- Resistance Level
- DUO $0.25
- CLDI $0.52
- Average True Range (ATR)
- DUO 0.03
- CLDI 0.07
- MACD
- DUO 0.01
- CLDI 0.02
- Stochastic Oscillator
- DUO 34.07
- CLDI 69.70
About DUO Fangdd Network Group Ltd.
Fangdd Network Group Ltd is an investment holding company. Through its subsidiaries, It is engaged in the provision of real estate information services through its online platform which also offers integrated marketing services for individual customers, real estate developers, and agents in China. Its SaaS-based solutions help real estate agents to connect with essential business resources, including customers, property listings, capital, and transaction data. The company generates the majority of its revenue from Base commission from transactions in China.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.